EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modulation of Patient-Derived Tumor Organoids by SARS-CoV-2 Variants Across Cancer Types: A Study Combining Morphology, Inflammation, and Whole-Exome Profiling

Danielle Ferreira iD, Tayanne Sassaro, Anael Viana Pinto Alberto, Marília de Melo iD, Audrien Alves Andrade, Beatriz Iandra Ferreira, Otacílio C Moreira iD, Daniel Moreira iD, Thiago Parente iD, Bruna Bordim iD, Júlia de Abreu, Fabiana Rondão und 7 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Danielle Ferreira und 18 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Applied Genomics and Bioinovations, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, RJ, Brazil. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Organoids, Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ), Oswaldo Cruz Foundation, Oncoclínicas Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer patients are highly vulnerable to severe COVID-19, requiring models that capture tumor–virus interactions. We investigated tumor- and variant-specific effects of SARS-CoV-2 Gamma and Delta infections using patient-derived organoids (PDOs) from metastatic breast, lung, and colorectal cancers. Viral infection was quantified by Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 24 h post-infection, and morphological changes and immune mediators were profiled. Genomic analysis using whole-exome sequencing was performed to identify contributing host-related gene alterations. The Delta variant produced consistently higher viral loads in lung and breast PDOs, while colorectal PDOs showed variable susceptibility. Infection led to reduced area and perimeter and increased circularity across all tumor types. Immune profiling revealed distinct responses: Gamma decreased Interferon alpha (IFNα) in lung PDOs and increased E-selectin in colorectal PDOs. Delta broadly reduced inflammatory mediators in lung [10 kDa interferon gamma-induced protein (IP-10) and Intercellular adhesion molecule 1 (ICAM-1)] and breast [Interleukin-6 (IL-6), Interleukin-13 (IL-13), and Interleukin-17A (IL-17A)] PDOs, while increasing Macrophage inflammatory protein 1-beta (MIP-1β) in colorectal PDOs. Host gene variants involved in trafficking (FYCO1 and RAB7A) and immune signaling (FOXA2, SFTPD, STAT3, and TET2) were associated with differential infection profiles. These findings show that SARS-CoV-2 induces variant- and tumor-specific morphological and immunological changes in cancer PDOs, highlighting the potential of this model to unravel host–virus interactions and identify genetic factors that shape infection outcomes in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19OrganoidsNeoplasmsHumansFemaleExome SequencingInflammationLung NeoplasmsBreast NeoplasmsColorectal NeoplasmsViral Load

Stichwörter der Autor:innen

SARS-CoV-2 infection modelsSARS-CoV-2 variantsbreast cancercolorectal cancerlung cancermorphological profilingpatient-derived organoidsprecision oncologytumor–virus interactions

Autor:innen und Institutionen

  • Laboratory of Applied Genomics and Bioinovations, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, RJ, Brazil.
  • Invitrocue Brasil, São Paulo 04513-020, SP, Brazil.
  • Integrated Center for Translational Oncology Research (CIPOT), Center for Technological Development in Health, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil.
  • Next Generation Sequencing Facility, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, RJ, Brazil.
  • Molecular Virology and Parasitology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, RJ, Brazil.
  • Molecular Analysis Facility, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, RJ, Brazil.

ORCID-Profile: Danielle Ferreira, Marília de Melo, Otacílio C Moreira, Daniel Moreira, Thiago Parente, Bruna Bordim, Carlos Gil Ferreira, Elen de Souza, Mariana Waghabi, Tatiana Tilli

Förderung

  • Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
  • Oswaldo Cruz Foundation
  • Oncoclínicas Institute
  • Oswaldo Cruz Institute

Zitieren

APA

Ferreira, D., Sassaro, T., Alberto, A. V. P., de Melo, M., Andrade, A. A., Ferreira, B. I., Moreira, O. C., Moreira, D., Parente, T., Bordim, B., de Abreu, J., Rondão, F., Canedo, J., Ferreira, C. G., de Souza, E., Moreira, A., Waghabi, M., Zalis, M. G., & Tilli, T. (2026). Modulation of Patient-Derived Tumor Organoids by SARS-CoV-2 Variants Across Cancer Types: A Study Combining Morphology, Inflammation, and Whole-Exome Profiling. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031156

Vancouver

Ferreira D, Sassaro T, Alberto AVP, de Melo M, Andrade AA, Ferreira BI, et al. Modulation of Patient-Derived Tumor Organoids by SARS-CoV-2 Variants Across Cancer Types: A Study Combining Morphology, Inflammation, and Whole-Exome Profiling. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031156

BibTeX
@article{Ferreira2026,
  author = {Ferreira, Danielle and Sassaro, Tayanne and Alberto, Anael Viana Pinto and de Melo, Marília and Andrade, Audrien Alves and Ferreira, Beatriz Iandra and Moreira, Otacílio C and Moreira, Daniel and Parente, Thiago and Bordim, Bruna and de Abreu, Júlia and Rondão, Fabiana and Canedo, Jorge and Ferreira, Carlos Gil and de Souza, Elen and Moreira, Aline and Waghabi, Mariana and Zalis, Mariano Gustavo and Tilli, Tatiana},
  title = {Modulation of Patient-Derived Tumor Organoids by SARS-CoV-2 Variants Across Cancer Types: A Study Combining Morphology, Inflammation, and Whole-Exome Profiling},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031156}
}
Kostenlos starten →